10 | Health Matters: Providence St. Jude Medical Center
Cutting-edge research to create
better solutions for prostate cancer
Providence St. Jude Crosson
Cancer Institute oncologists
are aggressively pursuing new
answers to metastatic prostate
cancer, including research into
an innovative immunotherapy
called AMG 509.
We are one of only a few dozen hospitals in the world and just three in California—along
with City of Hope and UCSF—to offer Phase I trials of this first-in-class antibody capable
of targeting prostate cancer cells.
The AMG 509 antibody binds to two different proteins, one commonly found on the surface
of prostate cancer cells and one on the immune system's T cells. "AMG 509 triggers an
activation of the patient's T cells and redirects them to cluster on and eradicate cancer
cells," explains Yung Lyou, MD, a Crosson Cancer Institute genitourinary oncologist who
specializes in prostate, kidney and bladder cancers.
Men with metastatic prostate cancer who have not responded to or have refused a taxane
regimen are currently being enrolled.
To learn more about any of the research trials currently underway for a wide range of cancers,
please call our oncology research department at 714-446-5177.
